netFormulary NHS
Sunderland Joint Formulary
NHS Sunderland Clinical Commissioning Group
South Tyneside and Sunderland NHS Foundation Trust
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Chapter Links...
 Details...
08.02.04  Expand sub section  Other immunomodulating drugs
BCG Connaught
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Vial: 81mg for bladder instillation

 
   
Brodalumab (Kyntheum ® )
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

210mg solution for infusion

Brodalumab for treating moderate to severe plaque psoriasis (TA511) 21.3.18

 
   
Cemiplimab (Libtayo®)
View adult BNF View SPC online
Formulary
Red
Cancer Drugs Fund

Cemiplimab (Libtayo®) is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic cutaneous squamous cell carcinoma in adults when curative surgery or curative radiotherapy is not appropriate.

It is recommended only if the conditions in the managed access agreement are followed.

 
Link  NICE TA 592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
   
Dimethyl fumarate
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Capsules: 120mg, 240mg

 
Link  NICE TA 303: Teriflunomide for treating relapsing–remitting multiple sclerosis
Link  NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
   
Cytotoxic Drug Dinutuximab beta (Qarziba®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
NHS England
  • 20mg/4.5mL concentrate for solution for infusion
  • Approved for the treatment of high-risk neuroblastoma in people aged 12 months and over in line with NICE 
  • Link  NICE TA 538: Dinutuximab beta for treating neuroblastoma
       
    Durvalumab (Imfinzi®)
    View adult BNF View SPC online
    Formulary
    Red
    Cancer Drugs Fund

    Durvalumab (Imfinzi®) monotherapy is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced unresectable non-small cell lung cancer in adults whose tumours express PD‑L1 on at least 1% of tumour cells and whose disease has not progressed after platinum-based chemoradiation only if:

    • they have had concurrent platinum-based chemoradiation, and
    • the conditions in the managed access agreement are followed.
     
    Link  NICE TA 578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
       
    Fingolimod
    View adult BNF View SPC online
    Formulary
    Red

    Capsules: 500microgram - - approved for the treatment of highly active relapsing–remitting multiple sclerosis in line with NICE - approved for patients who have progressed on glatiramer acetate and for those patients who are at high risk of progressive multifocal leukoencephalopathy (PML) in line withNHS EnglandClinical Commissioning Policy

     
    Link  NICE TA 254: Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis
       
    Lenalidomide
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Capsules: 5mg, 10mg, 15mg, & 25mg

     
    Link  NICE TA 586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
    Link  NICE TA 587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
    Link  NICE TA171: Multiple myeloma - lenalidomide
    Link  NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
    Link  NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma
       
    Mifamurtide
    View adult BNF View SPC online
    Formulary
    Red

    Vial: 4mg

     
    Link  NICE TA 235: Mifamurtide for the treatment of osteosarcoma
       
    Nivolumab
    View adult BNF View SPC online
    Formulary
    Red

    Concentrate for IV infusion: 10mg in 1ml concentrate for IV infusion as (4ml, 10ml & 24ml vials)

     

     

     

    For the treatment of locally advanced or metastatic squamous nonsmall cell lung cancer (NSCLC) after prior chemotherapy in adults

     
    Link  NICE TA 417: Nivolumab for previously treated advanced renal cell carcinoma
    Link  NICE TA 462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
    Link  NICE TA 581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
    Link  NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
    Link  NICE TA 400: Nivolumab in combination with ipilimumab for treating advanced melanoma
    Link  NICE TA 558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
    Link  NICE TA 655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
       
    Pomalidomide (Imnovid®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund

    Capsules: 1mg, 2mg, 3mg, 4mg

     
    Link  NICE TA 427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
       
    Siponimod (Mayzent®)
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine
    NHS England

    Tablet: 250 micrograns and 2 mg

     
    Link  NICE TA 656: Siponimod for treating secondary progressive multiple sclerosis
       
    Teriflunomide
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Film coated tablets: 14mg

     
    Link  NICE TA303: Teriflunomide for relapsing remitting MS
       
    Thalidomide
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Capsules: 50mg


    - approved in combination with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma in line with NICE
    - approved for the treatment of bleeding from bowel angiodysplasia in patients with an inherited/acquired bleeding disorder on specialist advice only.
    -approved for the treatment of severe epistaxis as a result of hereditary haemorrhagic telangiectasia (HHT) who have failed all other treatments.

     
    Link  NICE TA 228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
       
    08.02.04  Expand sub section  Interferon Alfa
    Interferon alfa-2b
    View adult BNF View SPC online
    Formulary
    Red

    Multidose pen injections: 10 mega units, 30 mega units

     
       
    Peginterferon alfa-2a
    View adult BNF View SPC online
    Formulary
    Red

    Injections in prefilled syringes 135 microgram, 180 microgram
    Prefilled pens: 135 micrograms and 180 micrograms

     
    Link  NICE TA 106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
    Link  NICE TA 200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
    Link  NICE TA 300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
    Link  NICE TA 75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
    Link  NICE TA 96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
       
    Peginterferon alfa-2b
    View adult BNF View SPC online
    Formulary
    Red

    Prefilled injection pens: 50, 80, 100, 120, 150 micrograms
    -approved for chronic hepatitis C as peginterferon alffa 2a

     
       
    08.02.04  Expand sub section  Interferon beta
    Interferon beta-1a
    View adult BNF View SPC online
    Formulary
    Red

    Prefilled pen (Avonex): 30 micrograms (6 million units)
    Prefilled pen (Rebif): 22 microgram (6 million units) & 44 microgram (12 million units)
    Cartridge for use in rebismart device: 22 microgram per 0.5ml and 44 microgram per 0.5ml
    Prefilled pen: 44 microgram per 0.5ml (Rebidose)
    -approved for use when the cartridges and prefilled syringes are unsuitable.

     
       
    Interferon beta-1b
    View adult BNF View SPC online
    Formulary
    Red

    Vials for preparing 750 microgram in 3ml injection (Betaferon)
    Vials for preparing 250 microgram in 1ml injection (Extavia)

     
       
    Peginterferon beta-1a
    View adult BNF View SPC online
    Formulary
    Red

    Prefilled pen: 125 microgram (Plegridy)

     
    Link  NICE TA624:Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
       
    08.02.04  Expand sub section  Aldesleukin
    08.02.04  Expand sub section  Glatiramer acetate to top
    Glatiramer Acetate
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Prefilled syringe injection: 20mg

     
    Link  NICE TA 527: Beta interferons and glatiramer acetate for treating multiple sclerosis
       
    08.02.04  Expand sub section  Natalizumab
    Natalizumab
    View adult BNF View SPC online
    Formulary
    Red
    High Cost Medicine

    Vial for preparing infusions: 300mg in 15ml (20mg/ml)
    - approved for rapidly evolving severe relapsing remitting multiple sclerosis in line with NICE

     
    Link  NICE TA127: Multiple sclerosis - natalizumab
       
     ....
     Non Formulary Items
    Aldesleukin  (Proleukin®)

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
     
    Canakinumab  (Ilaris®)

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
     
    Cediranib  (Recentin®)

    View adult BNF View SPC online
    Non Formulary
     
    Cobimetinib  (Cotellic®)

    View adult BNF View SPC online
    Non Formulary
     
    Fampridine

    View adult BNF View SPC online
    Non Formulary
    High Cost Medicine
     
    Pemrolizumab  (Keytruda®)

    View adult BNF View SPC online
    Non Formulary
     
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Red

    Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist. These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.   

    Amber

    These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care. For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug. Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.   

    Green +

    Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case.  

    Green

    These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care. N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN.   

    netFormulary